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ABSTRACT Gaucher disease is caused by mutations in the
gene encoding the lysosomal enzyme glucocerebrosidase (GC).
Three clinical types of Gaucher disease have been defined
according to the presence (type 2 and 3) or absence (type 1) of
central nervous system disease and severity of clinical manifes-
tations. The clinical course of the disease correlates with the
mutation carried by the GC gene. To produce mice with point
mutations that correspond to the clinical types of Gaucher
disease, we have devised a highly efficient one-step mutagenesis
method—the single insertion mutagenesis procedure
(SIMP)—to introduce human disease mutations into the mouse
GC gene. By using SIMP, mice were generated carrying either the
very severe RecNciI mutation that can cause type 2 disease or the
less severe L444P mutation associated with type 3 disease. Mice
homozygous for the RecNciI mutation had little GC enzyme
activity and accumulated glucosylceramide in brain and liver. In
contrast, the mice homozygous for the L444P mutation had
higher levels of GC activity and no detectable accumulation of
glucosylceramide in brain and liver. Surprisingly, both point
mutation mice died within 48 hr of birth, apparently of a
compromised epidermal permeability barrier caused by defec-
tive glucosylceramide metabolism in the epidermis.
Gaucher disease, the most common lysosomal storage disease,
is caused by mutations in the gene encoding the lysosomal
enzyme, glucocerebrosidase (GC) (1–3). The deficiency of
enzyme activity results in the accumulation of the GC sub-
strate, glucosylceramide, leading to enlargement of liver and
spleen, lesions in the bones, and, in the most severe cases,
impairment of central nervous system function.
The disease has been classified into three clinical types based on
the presence or absence of central nervous system involvement and
disease severity. Type 1 Gaucher disease is the mildest form and
is without neurologic involvement. Type 2, the most severe form
of the disease, is characterized by an early onset of neurologic
disease and acute course. The type 3 disease is of intermediate
severity with a later onset of neurologic symptoms and a more
chronic course. The clinical type of Gaucher disease, an autosomal
recessive disorder, is dictated to a large extent by mutations carried
in the GC gene. For instance, the N370S (substitution of serine for
normal asparagine-370) mutation is diagnostic of type 1 disease.
Homozygosity for the L444P (substitution of proline for leucine-
444) mutation usually is associated with type 3 disease in the
Norrbottnian population in Sweden. An allele termed RecNciI
with two amino acid changes (substitution of proline for leucine-
444 and proline for alanine-456) is found frequently in type 2
patients and causes perinatal lethality in homozygous form (4, 5).
In most cases studied, Gaucher patients retain residual GC
enzyme activity and have at least one allele specifying an amino
acid substitution in the GC coding sequence (2). Homozygosity for
a GC null mutation has been shown to result in prenatal lethality
in humans (6). GC knockout mice with a total enzyme deficiency
die within 24 hr after birth with glucosylceramide storage in brain
and liver and severe epidermal abnormalities (7, 8).
To establish more authentic mouse models of Gaucher
disease we have devised a single insertion mutagenesis pro-
cedure (SIMP) to introduce mutations associated with type 2
(RecNciI) and type 3 (L444P) Gaucher disease into the murine
GC gene in embryonic stem (ES) cells. SIMP uses an insertion-
type targeting vector that results in duplication of the target
sequence on homologous integration. The vector is carefully
designed so that one genomic duplicant is an intact gene
structure with introduced mutations and the other genomic
duplicant is a truncated gene without function. The resulting
point mutation mice had levels of GC activity and glucosyl-
ceramide storage that corresponded to the relative severity of
the mutations. Unexpectedly, both mice died soon after
birth—irrespective of the level of enzyme activity.
MATERIALS AND METHODS
Targeting Vector Construction and ES Cell Targeting.
Genomic clones from a 129ysv strain library (Stratagene;
catalogue 946306) containing the mouse GC gene were iso-
lated by using a human GC cDNA probe (ATCC; catalogue
65696). One clone that covers the entire GC locus, F8, was
used to construct targeting vectors.
RecA-assisted restriction endonuclease (RARE) cleavage
was used to introduce point mutations into this genomic clone
(9). The 16-kb genomic DNA insert first was subcloned into the
pBluescript SK vector. RARE cleavage then was carried out
to specifically cut only the BamHI and PstI sites in exon 10 of
the GC gene to release the 80-bp sequence delimited by the
two restriction sites (Fig. 1 B and C). Two pairs of comple-
mentary oligonucleotides were synthesized to carry the desired
mutations (L444P or RecNciI) and the diagnostic BamHI(2)
site (Fig. 1C). Oligonucleotides were annealed and ligated into
the BamHI–PstI plasmid to create pBL444P and pBRecNciI.
The 7-kb HindIII fragments from pBL444P and pBRecNciI
plasmids were purified and ligated into the HindIII site of the
pMC1neopolyA vector (Stratagene; catalogue 213201) to gen-
erate targeting vectors TVL444P and TVRecNciI. In both
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vectors, the bacterial neomycin phosphotransferase (neo) cas-
sette is in the opposite orientation to the GC gene.
The targeting vector (20 mg) was linearized with EcoRV
endonuclease and electroporated into 5 3 106 J1 ES cells (in
a volume of 0.8 ml) at 400 V and 25 m (Bio-Rad). The
G418-resistant ES cells were obtained and screened by South-
ern analysis as described (10). Chimeric mice were established
from targeted ES cells as described (11).
Biochemical Analysis. Acid b-glucosidase activity was de-
termined in extracts of brain, liver, and skin. Aliquots (25 ml)
of the extracts were incubated with 250 ml of a solution
containing 5 mM 4-methylumbelliferyl-b-D-glucopyranoside
(Toronto Research Chemicals, Downsview, ON, Canada),
0.125 mM sodium taurocholate, and 0.1 M sodium acetate (pH
4.0) at 37°C for 30 min. The reaction was stopped with 1 ml of a
buffer containing 0.17 M glycine and 0.17 M sodium carbonate
(pH 10). Fluorescence was determined on a Ratio-2 System
fluorometer (Optical Technology Devices, Elmsford, NY).
Epidermis was separated from dermis after floating the skin
of 1-day-old mice on Dispase (Boehinger Mannheim, grade II)
diluted 1:1 in Hank’s buffer at 4°C overnight. Epidermal lipids
were extracted in chloroform-methanol-water (1:2:0.6, voly
volyvol) for 24 hr at 37°C. The total lipid extracts were applied
to TLC plates, and the chromatograms were developed twice
with chloroform-methanol-acetic acid (190:9:1, volyvolyvol).
After development, plates were air-dried, sprayed with 8%
(wtyvol) H3PO4 containing 10% (wtyvol) CuSO4, charred, and
quantitated by photodensitometry. Sphingolipids were iso-
lated from brain and liver, separated by HPTLC and were
quantitated as described (12).
FIG. 1. Introduction of L444P and RecNciI human Gaucher disease mutations by the SIMP strategy. (A) A general scheme of the SIMP strategy.
The ragged end of the gene in the targeting vector represents a truncation, filled bars represent the homology in the targeting vectors, hatched bars
represent the endogenous allele. (B) The specific SIMP scheme for the introduction of the L444P and RecNciI mutations into the GC locus. The wild-type
locus is shown on the top and the correctly targeted locus is shown on the bottom. The SIMP recombination step is shown in the middle. The filled boxes
represent the exons of the GC gene, open boxes represent the exons of the nearby metaxin gene, stippled boxes represent probes used in the Southern
analysis (probe I is a 0.7-kb KpnI fragment covering exon 6 and probe E is a 0.4-kb EcoRI fragment covering exon 1), filled bars represent the homology
in the targeting vectors, hatched bars represent the endogenous allele. RT-59, 59 primer used in the reverse transcription (RT)-PCR primer
(59-CACGAATTCACATCACCCACTTGGCTCAAG-39); RT-39, 39 primer used in the RT-PCR (59-GTCGAATTCATGTCCATGCTAAGC-
CCAGGT-39); B, BamHI; N, NciI; P, PstI; RV, EcoRV; Probe E, external probe; Probe I, internal probe. (C) The DNA sequence of the mouse GC exon
10 region. The vertical lines are exonyintron borders. The underlined sequences are oligonucleotides used in the RecA-assisted restriction endonuclease
cleavage experiment. The mutations are indicated above and below the wild-type sequences. The mutated sequences between the two downward arrows
were used as top strand of the mutation inserts. The mutated sequences between the two upward arrows were used as bottom strand of the mutation inserts.
Both targeting vectors contained the change that eliminated the BamHI site and the L444P mutation. In addition, the RecNciI vector contain the L456P
change. (D) The expected sizes of BamHI restriction fragments of wild-type and targeted GC genes detected by the I (internal) and E (external) probes.
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Pathology. Twelve newborn mice (two each of homozygotes
for the L444P allele, RecNciI allele, the GC duplication
without mutations and corresponding normal controls) were
killed by ether inhalation and fixed by immersion in 0.1 M
phosphate-buffered 4% paraformaldehyde. The tail and hind
limb of some mice were removed before fixation for genotyp-
ing. The bodies of these mice were bisected sagittaly through
the midline. The left half was embedded in paraffin and used
for the light microscopic study. The right half was coronally
sectioned, rostral to caudal, and pieces of cerebrum, cerebel-
lum, brainstem, spinal cord, a portion of liver and skin from the
back of the neck at the midline (nuchal region) were processed
by plastic embedding for light and electron microscopic stud-
ies. Paraffin-embedded portions of the mice were sectioned (5
microns) and stained with solochrome and eosin and Luxol fast
blue-periodic acid Schiff stains. Plastic embedded tissue was
sectioned (1 micron) and stained with toluidine blue.
RESULTS
Scheme of SIMP. Homologous integration of insertion-type
targeting vectors results in a duplication of the entire genomic
segment carried by the vector (13, 14) (Fig. 1A). In our experi-
mental design, the genomic segment in the insertion-type target-
ing vector, containing the nucleotide changes to be introduced
into the genome, is truncated at the 59 end to render the gene
nonfunctional. After homologous recombination, the resulting 59
genomic duplicant is a complete gene with mutations transferred
from the targeting vector; the resulting 39 genomic duplicant is a
truncated, nonfunctional gene fragment. In summary, this pro-
cedure (Fig. 1A) results in the introduction of desired mutations
into the GC gene in one homologous integration step.
For introduction of the L444P and RecNciI mutations into
the mouse GC gene, we constructed the TVL444P and TVRec-
NciI insertion-type targeting vectors (Fig. 1B). Each contained
the pMC1neoPolyA cassette as a positive selection marker
(15). TVL444P carried nucleotide changes that resulted in the
substitution of proline for leucine-444 and in the elimination
of a BamHI site 36 bp upstream with a neutral codon change
to facilitate detection by Southern analysis (Fig. 1C). TVRec-
NciI carried the same changes as in TVL444P with an addi-
tional substitution of proline for alanine-456 that directly
eliminated a PstI site (Fig. 1C). In both vectors, the L444P
exchange created a novel NciI site. In patients with the
RecNciI allele a third point mutation (G1597C) is present
together with the L444P and A456P changes (2, 3). Because
the G1597C mutation does not result in an amino acid change
(V460V), it was not included in the RecNciI targeting vector.
The targeting vectors were linearized with EcoRV endonu-
clease at a single site within the GC gene, establishing a
distance between the EcoRV cut and the mutations of '2.5 kb
(Fig. 1B). The targeting vectors spanned the entire 39 end of
the GC gene from exon 3 through a portion of the downstream
metaxin gene (Fig. 1B) (16). The predicted genomic structure
resulting from homologous recombination is an intact 59 GC
gene copy with the introduced mutations, and a 39 GC gene
copy that is a truncated, nonfunctional gene fragment missing
the first two exons and upstream promoter sequences (Fig.
1B). The downstream metaxin gene remains intact.
Identification of Targeting Events. The linearized targeting
vectors were transferred into ES cells by electroporation, and
resulting G418r colonies were analyzed by Southern hybrid-
ization. On the basis of the double-strand break, gap repair,
and mismatch repair models for homologous recombination of
insertion-type vectors (17–19), three types of targeting events
could be observed: (i) the correct transfer of the mutations to
the 59 GC gene copy as discussed above, (ii) the incorrect
transfer of the mutations to the 39 truncated GC gene copy
caused by branch migration past the site of the mutations, and
(iii) the repair of the mutations back to the wild-type sequence
caused by gap repair or mismatch repair (Fig. 1 A). An internal
probe (probe I) and an external probe (probe E) were used to
identify these three different targeting events (Fig. 1B).
Genomic DNA from TVL444P transfected clones (4-13 4-9)
and TVRecNciI transfected clones (R-13R-9) were analyzed by
Southern blotting after digestion with BamHI restriction enzyme.
The correspondence of band size to GC genomic segment is shown
is Fig. 1D. The blot first was hybridized with the internal probe
(Fig. 2A; probe I, Top). The correctly targeted clones (4-13 4-4
and R-13R-4) showed three bands of equal intensity: a 6-kb band
from the wild-type (untargeted) allele, a 9-kb band from the 59 GC
copy of the targeted allele caused by the elimination of the BamHI
site in exon 10, and an 8-kb band from the truncated 39 GC copy.
The clones that had mutations incorrectly transferred into the
truncated 39 copy (4-5 and 4-6; and R-5 and R-6) showed two
bands of unequal intensity: a 6-kb band of double intensity derived
from both the wild-type allele and the 59 GC copy, and an 11-kb
band from the 39 GC copy caused by the elimination of the BamHI
site by the transferred mutations. The clones where repair of
mutations occurred (4-7 and 4-8, and R-7 and R-8) showed two
bands of unequal intensity: a double-intensity 6-kb band derived
from both the wild-type allele and the 59 GC copy, and a
FIG. 2. Analysis of three different homologous insertion events by the
two targeting vectors: TVL444P and TVRecNciI. (A) ES cell DNAs were
digested with BamHI, and the filter was probed with probe I (Upper) and
probe E (Lower), respectively. Clones 4-1 3 4-9, ES cell clones from
TVL444P targeting experiment; Clones R-1 3 R-9, ES cell clones from
TVRecNciI targeting experiment. (B) Sequence analysis of the mouse GC
transcripts from ES cells. cDNA clones, obtained by reverse transcription–
PCR, of wild-type and targeted alleles were sequenced with an automated
DNA sequencer (Applied Biosystems model 373A). Only mutated amino
acids are labeled. Nucleotide mutations are indicated by black dots.
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single-intensity 8-kb band from the truncated 39 GC copy. In
clones 4-9 and R-9 the targeting vectors were randomly integrated
into the genome. In these cases, the ends of the vectors are likely
lost during insertion because of exonuclease activity and the lack
of a repair function. Because the probe I hybridizes to these ends,
nontargeted clones show either weak bands of random sizes or no
band other than the 6-kb band from the wild-type allele.
The same blot of BamHI-digested genomic DNA was
stripped and rehybridized with the external probe (Fig. 2 A;
probe E, Lower) derived from a region around exon 1. Probe
E detects fragments of the wild-type gene (6 kb) and the 59 GC
copy fragment with the mutation (9 kb). It does not detect the
truncated 39 copy of the targeted allele caused by the absence
of exons 1 and 2. Correctly targeted clones (4-13 4-4 and R-1
3R-4) showed 6-kb and 9-kb bands as expected. Other clones,
such as those with mutations in the 39 duplication, with
mutations repaired and with a untargeted GC gene, showed
only the 6-kb wild-type band and, thus, cannot be distinguished
from one another with this probe.
Table 1 provides a summary of the three targeting events
from experiments using the two vectors. Both vectors gave
similar frequencies for the desired genomic changes (31% for
TVL444P and 26% for TVRecNciI) and for total targeting
(45% for TVL444P and 50% for TVRecNciI). For a 2.5-kb
distance between mutation and the cutting site in our vectors,
the percentages for the correct transfer of the mutation among
all the targeting events was 71% for TVL444P (17y24) and
50% for TVRecNciI (14y27), a reasonable frequency to enable
successful transfer of mutations.
The existence of human mutations in the GC transcripts was
confirmed by cloning and sequencing the reverse transcription–
PCR products derived from the targeted GC transcripts in ES
cells. The sequencing results showed that the desired changes (Fig.
1C), carried by the L444P and RecNciI targeting vectors, were
precisely transferred into the GC gene transcripts (Fig. 2B). In
addition, no alterations were detected around the EcoRV cleavage
site (data not show). This is consistent with previously reported
efficient double-strand gap repair in gene targeting (19).
Mice with Type 2 and 3 Gaucher Disease Mutations. The
L444P- and RecNciI-targeted ES clones were injected into
C57BLy6 mouse blastocysts, and highly chimeric male mice
were produced that transmitted the targeted alleles through
the germ line. The heterozygotes were intercrossed to obtain
mice homozygous for each mutated gene. Homozygotes for
both genotypes were obtained in the expected Mendelian ratio.
Both types of homozygous mice appeared abnormal at birth
(Fig. 3). The RecNciIi mouse was the most severely affected
with small size, poor turgor and an extremely red, wrinkled
appearance. These mice appeared not to feed as evidenced by
the absence of milk in their stomachs (Fig. 3A). The skin of the
L444P mice was also abnormally red and wrinkled, especially
around the torso area, but was less severely affected than the
RecNciI mouse. The skin turgor of L444P mice was much
improved compared with the RecNciI mouse. The improved
hydration may be caused by the ability of the L444P mice to
feed as evidenced by milk in the stomach (Fig. 3A). Both the
RecNciI and L444P mice died within 24–48 hr after birth.
Light microscopic examination of the brain, spinal cord, and
visceral organs of the RecNciI and L444P mice failed to dem-
onstrate abnormal macrophages (Gaucher cells). In the skin of
point mutation mice and controls, four layers—basal (stratum
basale), spinous (stratum spinosum), granular (stratum granulo-
sum), and cornified (stratum corneum)—all were identified in the
epidermis. All except the cornified layer appeared similar to the
corresponding layers of control mice. In control mice, the cor-
nified layer consisted of loosely stacked eosinophillic membra-
nous structures, whereas in the point mutation mice the cornified
layer was compact and basophilic; the eosinophillic membranous
structures were scarce (Fig. 3B). The abnormal cornified layer
appeared slightly thicker in RecNciI mice than in L444P mice. On
Luxol fast blue-periodic acid Schiff sections (PAS) (not shown),
PAS-positive granules in the granular and spinous layers were
more prominent in the point mutation mice than in control mice.
These PAS-positive granules, indicative of glycocojugate accu-
mulation, appeared to be more conspicuous in the RecNciI mice
than in the L444P mice.
Northern analysis revealed that levels of brain GC mRNA in
both the RecNciI and L444P mice were similar to wild type (Fig.
4A). The expression of the downstream gene, metaxin, also was
found to be unaffected by the genomic changes in the GC allele.
A large reduction in GC enzyme activity was found in extracts
from liver, brain, and skin from both the L444P mouse and
RecNciI mouse (Fig. 4B). The activity in the L444P mouse tissues
was about 20% of normal activity compared with 4–9% residual
activity found in the RecNciI mouse tissues. Analysis of the
sphingolipid fractions of brain and liver from the point mutation
mice demonstrated glucosylceramide accumulation in the Rec-
NciI mouse but not in the L444P mouse (Fig. 5A). In epidermis,
abnormally high glucosylceramide accumulation was found in
both mutant mice together with a lower than normal level of
ceramides. The glucosylceramide and ceramide levels were most
severely affected in the RecNciI mice (Fig. 5B).
To demonstrate that the severe phenotypes of the RecNciI
and L444P mice were the result of point mutations introduced
into the GC gene and not the result of a locus rearrangement
induced by the targeting procedure, we established mice by
using ES cells with the GC duplication but without human
point mutations (clone 4-7; Fig. 2A). Mice homozygous for this
GC configuration appear normal at birth, are viable into
adulthood, are fertile, have normal levels of GC activity, and
have a normal epidermal structure (not shown).
DISCUSSION
The introduction of point mutations into the mouse genome is an
important refinement of the original gene targeting technique.
iRecNciI and L444P mice refer to homozygotes for the RecNciI and
L444P targeted alleles, respectively.
FIG. 3. Phenotypes of RecNciI and L444P mice after birth. (A)
Photographs of the mice within 12 hr after birth. The arrow denotes the
presence of milk in the stomach. Note the smaller size and wrinkled skin
of the RecNciIyRecNciI mouse. The skin of the L444PyL444P mouse is
less severely wrinkled. The bracket indicates the sites where skin samples
were taken for the photomicrographs in B. (B) Section of epidermis
(3150). Stratum corneum (SC) of RecNciIyRecNciI and L444PyL444P
mice are compacted and less eosinophillic compared with the loosely
packed eosinophillic SC in the wild-type mouse. No significant differences
are noted in the three other layers of the epidermis (EP) (stratum basale,
stratum spinosum, and stratum granulosum) or the dermis (D).
Table 1. Summary of the three targeting events by using the














TVL444P 54 17 (31%) 4 3 24 (45%)
TVRecNciI 54 14 (26%) 7 6 27 (50%)
2506 Medical Sciences: Liu et al. Proc. Natl. Acad. Sci. USA 95 (1998)
Several strategies have been developed based on various vector
designs. Generally, they can be divided into either one-step or
two-step procedures. The two-step procedures involve either an
insertion-type of homologous recombination event followed by a
single reciprocal intrachromasomal recombination event (20, 21)
or two replacement-type of homologous recombination events
(22–24). The one-step procedure (cotransfer) uses a replacement
vector with a mutated gene linked to a selectable marker placed
into a neutral site to substitute for the wild-type gene (25).
Neither the two-step procedure nor the one-step cotransfer
procedure have been successful thus far in producing mice with
point mutations in the GC gene. We were not able to introduce
point mutation into the GC locus with a two-step procedure
because of low second-step targeting efficiency (Y.L. and R.L.P.,
data not shown). The one-step cotransfer procedure was also
unsatisfactory; in an attempt to transfer the N370S mutation, the
neo marker placed at the end of the GC gene unexpectedly
disrupted the downstream metaxin gene, resulting in embryonic
lethality (16).
To overcome difficulties associated with introducing point
mutations into the GC gene, we devised SIMP. SIMP has some
attractive features. First, the targeting vector contains a single
selectable marker and an uninterrupted segment of genomic
homology making vector construction simple. Second, the
frequency of homologous recombination is relatively high
because of the effectiveness of insertion-type targeting vectors
(26); our SIMP vectors showed very high targeting frequency
('50%) when compared with a similar-sized replacement
targeting vectors used in the previous mouse GC gene knock-
out experiment (7). Finally, only one step of ES cells culturing
and drug selection is required, increasing the likelihood that
the targeted ES cell will contribute to the germ line. The SIMP
methodology may be particularly useful in situations where
homologous recombination frequency is low, there is difficulty
in obtaining germ-line transmission, or the locus is crowded, as
is the case with the GC gene (27).
After homologous recombination, a properly configured SIMP
vector should produce a complete version of the targeted gene
with mutations in tandem with an inactive gene fragment. For this
to occur, SIMP vector must encompass the 59 or 39 end of the gene
to be targeted. Subsequently the targeted locus should be exam-
ined to exclude clones with unwanted events such as repair of the
mutations or transfer of the mutations into the inactive gene
duplication. Another consideration in constructing the SIMP
vector is the distance between the linearization site and the
mutation. On the basis of the double-strand break repair theory,
mutations very close to the double-strand break will tend to be
lost or transferred to the truncated duplication. In our experi-
ments, the 2.5-kb distance between the linearization site and the
mutation resulted in a high frequency of faithful transfer of the
mutation into the GC gene.
The locus duplication occurring as a result of SIMP was
found not to influence the expression of either GC or the
closely adjacent gene, metaxin. To prove that the phenotypes
of the mutant mice were not the result of the genomic
rearrangement, we established a mouse with the same dupli-
cation as in the L444P and RecNciI mice but without the point
mutations. The ES cells used to produce the mice were
obtained as one of the targeting events obtained by using SIMP
(Fig. 1A, event III). The mice with the GC duplication without
point mutations were phenotypically normal—without neona-
FIG. 4. Expression of GC mRNA and enzyme in RecNciI and
L444P mice. (A) A Northern blot with 5 mg of brain poly(A)1 RNA
from a RecNciI homozygote mouse, a L444P homozygote mouse, a
L444P heterozygote mouse, and a wild-type mouse. The blot first was
probed with a mouse GC cDNA. After stripping, it was reprobed with
a mouse metaxin cDNA. Finally, it was stripped once more and probed
with a human actin cDNA. (B) Acid b-glucosidase activity was
determined in extracts of liver, brain, and skin from homozygote
L444P and RecNciI mice. Tissues from three mice of each genotype
were assayed. The assays were repeated three times. The activity
(6SD) is expressed as nmol substrate cleavedyhr per mg of protein.
FIG. 5. Sphingolipid accumulation in tissues from RecNciI and
L444P mice. (A) Lipid profiles from brain and liver. Each lane represents
a portion of the material derived from a single mouse (L444P, RecNciI,
or wild type). The position of the glucosylceramide standard is indicated.
(B) The levels of total ceramides (Cer) and glucosylceramides (GlcCer)
in epidermis from RecNciI and L444P mice.
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tal lethality, with wild-type levels of GC enzyme, and with no
epidermal pathology—demonstrating that the introduced
point mutations were responsible for the striking phenotype of
the L444P and RecNciI mice.
The RecNciI mouse had a severe deficiency in GC enzyme
activity, did not feed, and died within 24 hr. The mouse showed
epidermal abnormalities and glucosylceramide storage in the
brain, liver, and skin. These features of the RecNciI mouse
appear virtually identical to the previously described GC
knockout mouse, suggesting that the RecNciI mutation results
in a null allele. Consistent with this conclusion is the perinatal
lethal phenotype of Gaucher disease infants homozygous for
the RecNciI allele (4, 5), and the finding that human RecNciI
mutant enzyme has little or no GC activity (28, 29).
By contrast, the L444P mouse had higher levels of GC activity—
about 20% of normal—with no detectable storage of glucosylce-
ramide in brain and liver at 1 day of age. Expression studies with
human GC carrying the L444P change had shown that the mutant
enzyme retains partial activity (28, 29). Compared with the
RecNciI mouse, the L444P mouse had an improved physical
condition with better hydration and an ability to feed. Unexpect-
edly, this mouse also did not survive past 24–48 hr after birth.
Previous work with the GC knockout mouse demonstrated an
altered skin permeability barrier resulting from elevated glucosyl-
ceramide and reduced ceramide in the epidermis (30). Similar skin
changes—increased glucosylceramide storage, lowered ceramide
content, and abnormal stratum corneum—were present in both
point mutation mice. With the lack of neuronal and visceral
glucosylceramide storage in the L444P mice, their rapid demise
seems likely a consequence of severe stratum corneum abnormal-
ities and compromised skin barrier function. Although neurologic
dysfunction cannot be ruled out in the RecNciI and GC knockout
mice because both have glucosylceramide storage in brain—
abnormal skin barrier function must be a major factor limiting
their life span.
Ceramides are essential components of the epidermal per-
meability barrier in the stratum corneum and may be derived
in part from glucosylceramides by the action of GC (30). The
reaction presumably takes place in the extracellular spaces of
the stratum corneum after extrusion of the glucosylceramides
from the epidermal lamellar bodies. The ceramides and other
lipids then are assembled into lamellar layers which function as
the permeability barrier. That GC activity is essential for this
process was clearly illustrated by the altered barrier function
and epidermal glucosylceramide storage in the completely
enzyme deficient GC knockout mouse (30). An altered per-
meability barrier in the RecNciI mouse also might be expected
because the mutation effectively produces a null allele. The
abnormal skin manifestation in the L444P mice, however, was
unexpected in light of their residual level of GC activity that
is sufficient to prevent glucosylceramide storage in brain and
liver. Epidermal abnormalities are not observed in Gaucher
patients homozygous for the L444P mutation or in patients
carrying other mutations resulting in residual GC activity. This
difference between rodents and humans may reflect the
differences in skin barrier formation during fetal development.
In rodents a competent skin permeability barrier forms very
late in gestation—1–2 days before birth (31, 32). A GC-
mediated conversion of glucosylceramide to ceramide occurs
during this period to produce a competent barrier (31). The
residual level of GC activity in the L444P mice may not be
sufficient to completely process the epidermal glucosylceram-
ide in this short time period during gestation. In humans, the
permeability barrier normally forms well before birth at be-
tween 30 and 34 weeks of gestation (33). The levels of residual
GC activity in most forms of Gaucher disease are apparently
sufficient to process epidermal glucosylceramide to ceramide
before term birth at 40 weeks. An exception is seen with the
Gaucher disease ‘‘collodion babies’’ exhibiting congenital ich-
thyosis and essentially no residual enzyme activity (8, 34).
Infants homozygous for the RecNciI mutation have been
described to have a severe skin phenotype (4, 5).
Another factor contributing to the glucosylceramide storage in
epidermis but not in brain and liver in the L444P mouse could be
related to biochemical differences of the glucosylceramides found
in different tissues. Skin contains glucosylceramides with addi-
tional hydroxyl groups and with very long chain fatty acids, in
addition to common types of glucosylceramides like those found
in brain and liver (35). The L444P mutation may render the GC
enzyme less active against the hydroxylated glucosylceramides
with long chain fatty acids than against the common types of
glucosylceramides, resulting in storage restricted to epidermis.
Establishment of a Gaucher disease model with a longer life
span will be important for both investigating the complex
pathogenesis of the disorder and evaluating new therapeutic
approaches such as gene therapy and the use of glycolipid
synthesis inhibitors. Our results show that the differences in
skin biology between mice and humans must be taken into
account in any strategy to produce a model of late onset
disease. Possible approaches include preservation of epider-
mal GC activity by a transgene in the context of an enzyme-
deficient animal or conditional gene disruption after the
formation of the epidermal permeability barrier.
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